PAHC
Phibro Animal Health Corporation NASDAQ Listed Apr 11, 2014$43.45
After hrs
$39.85
-0.38%
Mkt Cap $1.8B
52w Low $19.17
59.3% of range
52w High $60.08
50d MA $54.12
200d MA $42.98
P/E (TTM)
46.1x
EV/EBITDA
11.8x
P/B
7.8x
Debt/Equity
2.7x
ROE
21.8%
P/FCF
24.7x
RSI (14)
—
ATR (14)
—
Beta
0.69
50d MA
$54.12
200d MA
$42.98
Avg Volume
292.2K
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Glenpointe Centre East · Teaneck, NJ 07666-6712 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.72 | 0.76 | +5.6% | 58.50 | -15.4% | -26.2% | — | — | — | — | — |
| Feb 4, 2026 | AMC | 0.69 | 0.87 | +26.1% | 41.00 | +5.3% | +22.0% | +29.4% | +26.5% | +26.2% | +25.7% | — |
| Nov 5, 2025 | AMC | 0.59 | 0.73 | +23.7% | 41.15 | +0.3% | +4.6% | +6.3% | +11.4% | +10.2% | +10.1% | — |
| Aug 27, 2025 | AMC | 0.52 | 0.57 | +9.6% | 32.20 | +17.7% | +19.4% | +15.1% | +13.9% | +18.6% | +21.3% | — |
| May 7, 2025 | AMC | 0.52 | 0.63 | +21.2% | 19.39 | -0.4% | +14.7% | +15.9% | +26.4% | +26.9% | +20.5% | — |
| Feb 5, 2025 | AMC | 0.40 | 0.54 | +35.0% | 22.37 | +6.8% | +9.9% | +5.9% | +17.2% | +16.8% | +10.0% | — |
| Nov 7, 2024 | AMC | 0.25 | 0.35 | +40.0% | 23.50 | -0.6% | +1.5% | +8.7% | +6.6% | +7.5% | +6.0% | — |
| Aug 28, 2024 | AMC | 0.34 | 0.41 | +20.6% | 20.81 | -5.6% | +3.2% | +0.9% | -4.5% | -5.6% | -6.7% | — |
| May 8, 2024 | AMC | 0.29 | 0.31 | +6.9% | 17.18 | -0.9% | +3.0% | +2.2% | +5.4% | +6.0% | +6.2% | — |
| Feb 7, 2024 | AMC | 0.27 | 0.33 | +22.2% | 10.67 | +5.0% | +7.4% | +8.4% | +14.1% | +6.2% | +12.0% | — |
| Nov 8, 2023 | AMC | 0.21 | 0.14 | -33.3% | 12.04 | -14.2% | -18.5% | -19.8% | -18.9% | -15.5% | -12.8% | — |
| Aug 30, 2023 | AMC | 0.40 | 0.38 | -5.0% | 14.83 | -3.9% | -5.9% | -2.2% | -9.4% | -12.9% | -15.8% | — |
| May 3, 2023 | AMC | 0.34 | 0.29 | -14.7% | 15.60 | -3.9% | -8.3% | -6.2% | -7.9% | -11.3% | -9.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $43.04 | $43.17 | +0.3% | +1.7% | +6.5% | +5.3% | +5.3% | +3.9% |
| Aug 29 | BofA Securities | Maintains | Underperform → Underperform | — | $38.46 | $38.25 | -0.5% | -3.6% | -4.6% | -0.7% | +1.6% | +2.6% |
| Jul 7 | JP Morgan | Upgrade | Neutral → Overweight | — | $28.00 | $29.63 | +5.8% | +6.8% | +7.6% | +12.1% | +11.2% | +10.0% |
| Jun 25 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $24.77 | $25.00 | +0.9% | -0.1% | +1.4% | +3.6% | +3.1% | +7.5% |
| May 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $19.39 | $19.32 | -0.4% | +14.7% | +15.9% | +26.4% | +26.9% | +20.5% |
| Feb 10 | Barclays | Maintains | Underweight → Underweight | — | $23.69 | $23.86 | +0.7% | +10.7% | +10.3% | +3.8% | +6.3% | +8.8% |
| Dec 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $22.64 | $22.63 | -0.0% | -1.3% | -6.1% | -3.7% | -4.2% | -4.4% |
| Nov 12 | Barclays | Maintains | Underweight → Underweight | — | $25.55 | $25.65 | +0.4% | -1.9% | -1.1% | -2.5% | -4.3% | -5.6% |
| Aug 30 | BofA Securities | Maintains | Underperform → Underperform | — | $21.47 | $21.59 | +0.6% | -2.2% | -7.5% | -8.5% | -9.5% | -9.4% |
| May 10 | Barclays | Maintains | Underweight → Underweight | — | $17.70 | $17.82 | +0.7% | -0.8% | +2.3% | +2.9% | +3.1% | +1.6% |
| Nov 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.04 | $10.33 | -14.2% | -18.5% | -19.8% | -18.9% | -15.5% | -12.8% |
| Sep 1 | Roth MKM | Maintains | Buy → Buy | — | $13.95 | $13.90 | -0.4% | +4.0% | -3.7% | -7.5% | -10.5% | -9.9% |
| Aug 31 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $14.83 | $14.25 | -3.9% | -5.9% | -2.2% | -9.4% | -12.9% | -15.8% |
| Aug 29 | Roth MKM | Maintains | Buy → Buy | — | $14.98 | $15.06 | +0.5% | -1.1% | -1.0% | -6.9% | -3.1% | -10.3% |
| Jul 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $14.78 | $14.89 | +0.7% | -3.9% | -2.8% | -2.0% | +0.3% | +0.5% |
| May 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $15.60 | $14.99 | -3.9% | -8.3% | -6.2% | -7.9% | -11.3% | -9.7% |
| Feb 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $15.90 | $16.34 | +2.8% | +0.0% | -0.9% | -0.4% | +1.1% | +2.5% |
| Dec 21 | Roth Capital | Maintains | Buy → Buy | — | $12.75 | $13.43 | +5.3% | +7.2% | +8.2% | +9.0% | +4.4% | +5.2% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $14.42 | $13.86 | -3.9% | -3.1% | -2.9% | -5.6% | -8.9% | -11.0% |
| Sep 16 | Barclays | Maintains | Underweight → Underweight | — | $14.29 | $14.13 | -1.1% | +1.3% | -1.0% | -1.6% | -3.6% | -6.3% |
| Aug 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $16.40 | $16.26 | -0.9% | -2.5% | -2.7% | -5.5% | -9.7% | -6.7% |
| Jul 25 | Barclays | Downgrade | Equal Weight → Underweight | — | $19.83 | $18.63 | -6.1% | -5.1% | -2.9% | -2.5% | -0.3% | -1.3% |
| Jan 10 | Barclays | Upgrade | Underweight → Equal Weight | — | $20.27 | $20.68 | +2.0% | +4.9% | +2.7% | +1.9% | +2.3% | +3.9% |
| Nov 18 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $21.68 | $21.55 | -0.6% | +0.5% | +0.5% | +2.4% | +0.6% | +1.5% |
| Jul 7 | Barclays | Downgrade | Equal Weight → Underweight | — | $28.78 | $26.95 | -6.4% | -7.0% | -11.3% | -10.6% | -5.7% | -10.8% |
| May 13 | Morgan Stanley | Maintains | Underweight → Underweight | — | $26.04 | $26.18 | +0.5% | +3.7% | +5.7% | +7.8% | +7.4% | +8.5% |
| May 8 | Credit Suisse | Maintains | Neutral → Neutral | — | $22.72 | $22.40 | -1.4% | -0.7% | +0.2% | -0.9% | +2.3% | +0.4% |
| Feb 6 | Gabelli & Co. | Downgrade | Buy → Hold | — | $27.38 | $26.14 | -4.5% | +0.5% | -1.3% | -1.8% | -1.6% | -1.1% |
| Jan 28 | Barclays | Upgrade | Underweight → Equal Weight | — | $24.84 | $26.41 | +6.3% | +4.7% | +2.0% | +0.3% | -4.5% | -4.4% |
| Sep 5 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $20.34 | $21.58 | +6.1% | +4.6% | +1.6% | +1.1% | +2.5% | +0.4% |
| Aug 29 | Bank of America | Maintains | Underperform → Underperform | — | $21.74 | $21.90 | +0.7% | -2.8% | -5.0% | -6.2% | -6.4% | -2.1% |
| Aug 29 | Barclays | Maintains | Underweight → Underweight | — | $21.74 | $21.90 | +0.7% | -2.8% | -5.0% | -6.2% | -6.4% | -2.1% |
| Aug 28 | Credit Suisse | Maintains | Neutral → Neutral | — | $31.57 | $23.25 | -26.4% | -31.1% | -33.0% | -34.6% | -35.4% | -35.6% |
| Jun 11 | Barclays | Maintains | Underweight → Underweight | — | $29.90 | $29.51 | -1.3% | -6.3% | -1.7% | -2.4% | -3.0% | -3.2% |
| May 9 | Gabelli & Co. | Upgrade | Hold → Buy | — | $30.86 | $31.84 | +3.2% | +0.8% | -3.2% | -7.4% | -7.3% | -7.8% |
| Aug 29 | Morgan Stanley | Maintains | Underweight → Underweight | — | $49.25 | $49.30 | +0.1% | -4.6% | -7.5% | -4.2% | -3.1% | -3.2% |
| Jul 5 | Barclays | Maintains | Underweight → Underweight | — | $46.85 | $47.15 | +0.6% | +0.6% | +0.9% | +0.9% | -0.5% | -0.2% |
| May 9 | Credit Suisse | Maintains | Neutral → Neutral | — | $44.25 | $44.55 | +0.7% | -0.7% | -1.6% | -1.0% | -1.2% | -2.6% |
| Feb 7 | Morgan Stanley | Maintains | Underweight → Underweight | — | $36.35 | $36.70 | +1.0% | +0.7% | -2.8% | -2.2% | -2.5% | -3.6% |
| Feb 6 | Credit Suisse | Maintains | Neutral → Neutral | — | $32.20 | $36.20 | +12.4% | +12.9% | +13.7% | +9.8% | +10.4% | +10.1% |
| Aug 31 | Credit Suisse | Maintains | Outperform → Outperform | — | $37.75 | $37.80 | +0.1% | -6.0% | -3.3% | -6.8% | -7.2% | -4.8% |
| Dec 15 | PiperJaffray | Maintains | Overweight → Overweight | — | $27.10 | $27.00 | -0.4% | +3.5% | +6.1% | +10.5% | +8.5% | +8.9% |
| Nov 11 | Macquarie | Downgrade | Neutral → Underperform | — | $29.55 | $27.35 | -7.4% | -2.9% | -2.2% | -3.9% | -4.7% | -4.2% |
| Nov 10 | Gabelli & Co. | Downgrade | Buy → Hold | — | $28.10 | $24.85 | -11.6% | +5.2% | +2.1% | +2.8% | +1.1% | +0.2% |
| Feb 17 | Macquarie | Maintains | Neutral → Neutral | — | $28.70 | $28.82 | +0.4% | -1.1% | -1.3% | -0.3% | -2.0% | -2.4% |
| Feb 3 | Credit Suisse | Maintains | Outperform → Outperform | — | $33.54 | $33.80 | +0.8% | +0.3% | +4.0% | +1.8% | +1.6% | +1.0% |
| Jan 15 | Barclays | Downgrade | Overweight → Underweight | — | $28.48 | $27.05 | -5.0% | +1.0% | +1.8% | +4.7% | +4.0% | +6.9% |
| Apr 24 | Barclays | Maintains | Overweight → Overweight | — | $33.21 | $33.24 | +0.1% | +0.0% | -1.4% | -0.8% | +2.0% | -4.4% |
| Apr 21 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $34.00 | $33.32 | -2.0% | -4.9% | -1.6% | -2.3% | -2.3% | -3.7% |
| Apr 2 | Macquarie | Maintains | Neutral → Neutral | — | $35.67 | $34.93 | -2.1% | -5.5% | -5.6% | -4.8% | -4.5% | -3.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 2,029 | $49.19 | $100K | 56,152 | -7.32% | — |
| May 7, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 1,149 | $48.31 | $56K | 58,181 | -7.32% | — |
| May 7, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 1,350 | $47.59 | $64K | 59,330 | -7.32% | — |
| May 6, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 1,406 | $58.13 | $82K | 60,680 | -7.32% | — |
| May 6, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 5,634 | $57.18 | $322K | 62,086 | -7.32% | — |
| May 5, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 776 | $56.37 | $44K | 67,720 | -7.32% | — |
| May 5, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 6,264 | $55.73 | $349K | 68,496 | -7.32% | — |
| Apr 30, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 1,235 | $53.32 | $66K | 74,760 | +3.22% | -18.84% |
| Apr 30, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 5,805 | $52.65 | $306K | 75,995 | +3.22% | -18.84% |
| Apr 29, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 3,038 | $53.21 | $162K | 81,800 | +3.22% | -18.84% |
| Apr 29, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 4,002 | $52.70 | $211K | 84,838 | +3.22% | -18.84% |
| Apr 28, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 797 | $56.69 | $45K | 88,840 | +3.22% | -18.84% |
| Apr 28, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 4,591 | $56.06 | $257K | 89,637 | +3.22% | -18.84% |
| Apr 28, 2026 | BENDHEIM JACKDir/Off | President and CEO | Sell | 1,652 | $55.10 | $91K | 94,228 | +3.22% | -18.84% |
8-K · 1.01
! Medium
Phibro Animal Health Corporation -- 8-K 1.01: Financing / Debt Agreement
Phibro Animal Health Corporation amended its financing agreement, potentially modifying debt terms or covenants that could affect the company's financial flexibility and borrowing costs for investors.
Apr 30
8-K · 7.01
! Medium
Phibro Animal Health Corporation Class A -- 8-K 7.01: Regulation FD Disclosure
Phibro Animal Health faces a potential product prohibition taking effect in 180 days, which could materially impact sales and operations depending on the ordinance's scope and affected markets.
Apr 27
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
PAHC's executive change could signal leadership instability or strategic repositioning, making investors question management continuity and future company direction during what may be a critical operational period.
Apr 14
8-K
Phibro Animal Health Corporation Class A -- 8-K Filing
Phibro Animal Health raised full-year guidance after exceeding expectations with faster-than-anticipated adoption of its newly integrated MFA portfolio in Q2 2026.
Feb 4
8-K · 8.01
!! High
Phibro Animal Health Corporation Class A -- 8-K 8.01: Material Event / Announcement
Phibro Animal Health (PAHC) announced a dividend payment to shareholders, signaling confidence in cash generation and commitment to returning capital to investors.
Feb 3
Data updated apr 26, 2026 6:31pm
· Source: massive.com